National Institutes of Health: Leukemia, Lymphocytic, Chronic, B-Cell trials

The registry lists 142 Leukemia, Lymphocytic, Chronic, B-Cell studies with National Institutes of Health as lead sponsor. 9 are open to participants now and 42 have results posted.

Early Phase 1 2Phase 1 78Phase 2 61Phase 3 6No phase 6(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• XK469R in Treating Patients With Refractory Hematologic CancerCompletedNCT00095797Phase 1
• 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
• Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00089154Phase 2
• Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00087425Phase 2
• CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00086840Phase 2
• FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaTerminatedNCT00079443Phase 2
• Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00079378Phase 1
• Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00077155Phase 1
• Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
• Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell TransplantationCompletedNCT00058305Phase 2
• Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
• Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
• Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic CancerActive, not recruitingNCT00039676
• Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00026182Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaWithdrawnNCT00024115Phase 1
• Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic LeukemiaTerminatedNCT00022971Phase 1
• Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00022581Phase 2
• Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT00019708Phase 1
• Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's LymphomaCompletedNCT00018954Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00017472Phase 1
• Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00017381Early Phase 1
• Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerCompletedNCT00010192Phase 1
• Thalidomide With or Without Fludarabine in Treating Patients With Hematologic CancerTerminatedNCT00009984Phase 2
• Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00006473Phase 2
• Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00006226Phase 2
• 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell LymphomaTerminatedNCT00005950Phase 2
• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or LeukemiaTerminatedNCT00005786Not applicable
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or LymphomaCompletedNCT00003970Phase 1
• Flavopiridol in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00003620Phase 2
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedNCT00003210Phase 2
• Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaCompletedNCT00003204Phase 3
• Bryostatin and Vincristine in B-Cell MalignanciesCompletedNCT00003166Phase 1
• Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's LymphomaCompletedNCT00002745Phase 2
• The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood CancersCompletedNCT00001873Phase 2
• Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow TransplantsCompletedNCT00001830Phase 1
• Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older AdultsCompletedNCT00001637Phase 2